DR Congo Ebola outbreak passes 11,000 confirmed cases
Government data show 11,042 confirmed Ebola cases and at least 5,387 deaths in DR Congo, in an outbreak of the Bundibugyo strain for which no approved vaccine or treatment exists.
The Ebola outbreak in the Democratic Republic of the Congo has now passed 11,000 confirmed cases. According to government data released on 10 November and reported by Al Jazeera, citing Reuters, there are 11,042 confirmed cases and at least 5,387 deaths. Al Jazeera describes it as the largest and deadliest Ebola outbreak in the country's history.
Key figures
- Eight of the DRC's 26 provinces are affected, according to Al Jazeera.
- Cases have also been reported elsewhere in Africa. Al Jazeera's earlier report said Kenya had reported nine cases including two deaths, and Nigeria one confirmed case, according to the WHO.
- The outbreak is the second largest on record, behind the 2014-2016 West Africa epidemic, which infected more than 28,600 people and killed more than 11,000, Al Jazeera reports.
A strain without an approved vaccine
The outbreak is caused by the Bundibugyo virus. The World Health Organization says there is no approved vaccine or treatment for it, though candidate products are in development. The WHO notes that Ebola fatality averages about 50%, with past outbreaks ranging from 25% to 90%, and that early supportive care such as rehydration improves survival. Approved vaccines and antibody treatments exist only for the Ebola virus (Zaire) species.
Earlier this month, according to Al Jazeera, WHO expert groups recommended adding trials of two new vaccines targeting Bundibugyo. They were developed by the University of Oxford, the Serum Institute of India and Moderna, and results are expected in early 2027. WHO chief Tedros Adhanom Ghebreyesus said vaccines are no substitute for early care, contact tracing, isolation and safe burials, and urged countries to lift travel restrictions, which he said "punish countries for doing the right thing".
Why it has spread
Al Jazeera reports that delayed detection, conflict and strained health services have let the virus spread faster than in previous outbreaks, and that many deaths have occurred outside treatment centres. The WHO says the virus spreads through direct contact with the blood or body fluids of a sick or deceased person, or contaminated objects, and that health workers are often infected when infection-control precautions are not strictly followed. The incubation period is 2 to 21 days, and people are not infectious before symptoms appear.
The WHO's fact sheet also records that the epidemic, described as affecting the DRC and Uganda, was determined to be a public health emergency of international concern on 17 May 2026.
Analysis: With no licensed vaccine for this strain, containment currently rests on classic public-health measures, and the vaccine trial results due in early 2027 are the next major milestone. Case counts can differ between sources: the African CDC reported 10,444 confirmed cases in early November, a figure consistent with rapid growth into the government's latest total.
Sources
Related stories
WHO warns drug resistance is outpacing global targets
WHO officials said on 16 November that progress against antimicrobial resistance is too slow, with a warning of up to 39 million deaths over 25 years, according to Al Jazeera.
WHO survey: climate-health plans rise, action still lags
A WHO survey of 146 countries finds over 90% now have climate and health focal points and more than half have plans, but financing, workforce and monitoring gaps are holding back implementation. The report lands as COP31 continues in Türkiye.
Daily GLP-1 pills raise hopes of closing diabetes care gap
Once-daily GLP-1 tablets could be cheaper and easier to store than injections, Al Jazeera reports. WHO backs the drugs conditionally but projects they will reach fewer than 10% of those who could benefit by 2030.
WHO issues new type 1 diabetes guidelines for World Diabetes Day
WHO has published new guidelines on insulin use in adults and its first on type 1 diabetes in children, both aimed at low-resource settings. A separate report asks whether daily pills could widen access to newer drugs.
